Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:compatibleWith |
type 1 diabetes
|
| gptkbp:contraindication |
gptkb:medullary_thyroid_carcinoma
gptkb:multiple_endocrine_neoplasia_syndrome_type_2 |
| gptkbp:discoveredIn |
2000s
|
| gptkbp:effect |
weight loss
lower blood glucose decrease glucagon secretion increase insulin secretion reduce appetite slow gastric emptying |
| gptkbp:example |
gptkb:albiglutide
gptkb:exenatide gptkb:liraglutide gptkb:semaglutide gptkb:dulaglutide |
| https://www.w3.org/2000/01/rdf-schema#label |
GLP-1 receptor agonists
|
| gptkbp:mechanismOfAction |
GLP-1 receptor activation
|
| gptkbp:prescribes |
endocrinologists
primary care physicians |
| gptkbp:regulatorApproval |
gptkb:FDA
gptkb:EMA |
| gptkbp:relatedTo |
incretin mimetics
|
| gptkbp:routeOfAdministration |
subcutaneous injection
oral (semaglutide) |
| gptkbp:sideEffect |
nausea
vomiting diarrhea pancreatitis |
| gptkbp:usedFor |
gptkb:type_2_diabetes
obesity |
| gptkbp:bfsParent |
gptkb:Type_2_diabetes
|
| gptkbp:bfsLayer |
5
|